These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11077130)

  • 1. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure.
    Dickstein K; Manhenke C; Aarsland T; McNay J; Wiltse C; Wright T
    Int J Cardiol; 2000 Sep; 75(2-3):167-76; discussion 176-7. PubMed ID: 11077130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Dickstein K; Manhenke C; Aarsland T; Køpp U; McNay J; Wiltse C
    Am J Cardiol; 1999 Jun; 83(12):1638-44. PubMed ID: 10392868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators.
    Swedberg K; Bergh CH; Dickstein K; McNay J; Steinberg M
    J Am Coll Cardiol; 2000 Feb; 35(2):398-404. PubMed ID: 10676687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
    Swedberg K; Bristow MR; Cohn JN; Dargie H; Straub M; Wiltse C; Wright TJ;
    Circulation; 2002 Apr; 105(15):1797-803. PubMed ID: 11956122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
    Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
    Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
    Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.
    Brynne L; McNay JL; Schaefer HG; Swedberg K; Wiltse CG; Karlsson MO
    Br J Clin Pharmacol; 2001 Jan; 51(1):35-43. PubMed ID: 11167663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress.
    Wenzel RR; Mitchell A; Siffert W; Bührmann S; Philipp T; Schäfers RF
    Br J Clin Pharmacol; 2004 May; 57(5):545-51. PubMed ID: 15089806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension.
    Kemme MJ; vd Post JP; Schoemaker RC; Straub M; Cohen AF; van Gerven JM
    Br J Clin Pharmacol; 2003 Jun; 55(6):518-25. PubMed ID: 12814444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure.
    Rodríguez-García JL; Paule A; Domínguez J; García-Escribano JR; Vázquez M
    Int J Cardiol; 1999 Aug; 70(3):293-301. PubMed ID: 10501344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of moxonidine on cardiac autonomic modulation.
    Kaya D; Barutcu I; Esen AM; Celik A; Onrat E
    Pacing Clin Electrophysiol; 2010 Aug; 33(8):929-33. PubMed ID: 20230461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model.
    Van Kerckhoven R; van Veen TA; Boomsma F; Saxena PR; Schoemaker RG
    Eur J Pharmacol; 2000 May; 397(1):113-20. PubMed ID: 10844105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
    Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
    Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
    De Tommasi E; Iacoviello M; Romito R; Ceconi C; Guida P; Massari F; Francolini G; Bertocchi F; Ferrari R; Rizzon P; Pitzalis MV
    Am Heart J; 2003 Nov; 146(5):E17. PubMed ID: 14597946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex.
    Szabo B; Fritz T; Wedzony K
    Br J Pharmacol; 2001 Sep; 134(2):295-304. PubMed ID: 11564647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of central sympathetic inhibition on heart rate variability during steady-state exercise in healthy humans.
    De Vito G; Galloway SD; Nimmo MA; Maas P; McMurray JJ
    Clin Physiol Funct Imaging; 2002 Jan; 22(1):32-8. PubMed ID: 12003097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.